VivaChek Snags Nearly $14.2M in Series C Round, Developing POCT Products

According to iyiou.com, VivaChek Laboratories, Inc. ("VivaChek") has completed its Series C financing of nearly 100 million yuan (US$14.2 million), co-led by Shanghai-based Dongfang Yirui Health Industry Investment Center ("Dongfang Yirui")and Hongcheng Capital. Proceeds of this financing will be used for the research and development of POCT (Point-of-Caring Testing) products and the expansion of the global market.

VivaChek was established in Wilmington, Delaware, USA in June 2013 with its primary function to serve the International market. Since then, it becomes a reliable manufacturer of POCT products and blood glucose monitoring systems with partners in over 70 countries worldwide. 

The manufacturing center of VivaChek, VivaChek Biotech Co., Ltd, located in Hangzhou, China, is a rapidly growing manufacturing center for IVD products and new product development. 

VivaChek has launched VivaChek^TM Ino and VivaChek^TM FAD Blood Glucose Monitoring Systems in the international and Chinese markets, helping people with diabetes to live in a healthier life. In addition, the company launched the POCT Immunofluorescence Analyzer in the International market in 2018, for rapid tests with cardiac markers, renal functions, tumor markers, diabetes, infection, and hormone tests.

In the field of POCT, VivaChek will start from the platform of quantitative immunofluorescence and focus on infection, heart disease, kidney disease, and cancer. So far, nearly 20 POCT products of VivaChek have been approved by CE or CFDA.

For market expansion, VivaChek will continue to explore the American and the European market, and firmly grasp the opportunities in the domestic market.

Founded in May 2016, Dongfang Yirui is a Shanghai-based investment company. Its business covers investment management, asset management, and industrial investment.